ULTRAVIST 150 Drug Patent Profile

When do Ultravist 150 patents expire, and what generic alternatives are available?

Ultravist 150 is a drug marketed by Bayer Hlthcare and is included in one NDA.

The generic ingredient in ULTRAVIST 150 is iopromide. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the iopromide profile page.

Summary for ULTRAVIST 150

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	86
Clinical Trials:	11
Patent Applications:	2,584
DailyMed Link:	ULTRAVIST 150 at DailyMed

Recent Clinical Trials for ULTRAVIST 150

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Duke Clinical Research Institute	Phase 4
GE Healthcare	Phase 4
Bayer	Phase 4

See all ULTRAVIST 150 clinical trials

Pharmacology for ULTRAVIST 150

Drug Class	Radiographic Contrast Agent
Mechanism of Action	X-Ray Contrast Activity

US Patents and Regulatory Information for ULTRAVIST 150

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	ULTRAVIST 150	iopromide	INJECTABLE;INJECTION	020220-004	May 10, 1995		DISCN	Yes	No

Expired US Patents for ULTRAVIST 150

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	ULTRAVIST 150	iopromide	INJECTABLE;INJECTION	020220-004	May 10, 1995

International Patents for ULTRAVIST 150

See the table below for patents covering ULTRAVIST 150 around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	2909439
Yugoslavia	61780
Spain	491254
South Africa	8001350

ULTRAVIST 150 Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Ultravist 150

Introduction to Ultravist 150

Ultravist 150, a non-ionic, iodinated contrast medium, is widely used in medical imaging procedures such as computed tomography (CT) scans, angiography, and other radiographic examinations. It is manufactured by Bayer and plays a crucial role in the diagnostic imaging market.

Global Export and Market Trends

Export Volume and Growth

• According to Volza's global export data, from March 2023 to February 2024, there were 394 shipments of Ultravist, marking a 4% growth rate compared to the preceding twelve months. However, in February 2024 alone, there was a year-on-year decline of 59% and a sequential decline of 48% from January 2024[1].

Key Exporters and Importers

• Germany leads the world in Ultravist exports, followed by India and Turkey. The primary importers of Ultravist include Argentina, India, and Colombia[1].

Financial Performance of Bayer's Pharmaceuticals Division

Revenue and Sales Growth

• The Pharmaceuticals division of Bayer, which includes the Ultravist product family, saw significant growth in the first quarter of 2024. Sales of prescription medicines increased by 3.9% (currency- and portfolio-adjusted), with the Radiology business, including Ultravist, registering a growth of around 10%[3].

Segment Performance

• The success of Ultravist is part of the broader performance of Bayer's Pharmaceuticals division, which also includes other successful products like Nubeqa, Kerendia, and Eylea. These products have contributed to the division's overall revenue growth[3].

Pricing and Market Dynamics

Pricing Trends

• The pricing of Ultravist varies based on the volume and concentration of the product. For instance, shipments of Ultravist 370 BT 10x100ml and Ultravist 300 BT 1x500ml have been recorded with varying prices, indicating a dynamic pricing strategy based on market demand and competition[1].

Competitive Landscape

• The market for contrast media is competitive, with other major players offering similar products. Despite this, Ultravist has maintained its market share due to its efficacy and the strong brand presence of Bayer in the pharmaceuticals sector[3].

Financial Guidance and Outlook

Bayer's Financial Outlook

• For the full year 2024, Bayer has reaffirmed its financial guidance, expecting stable or slightly increased sales in the Pharmaceuticals division. This includes continued growth in the Radiology segment, which benefits Ultravist sales[3].

Cost Management and R&D Investments

• Bayer has been focusing on cost management and investing in research and development, particularly in cell and gene therapy and chemoproteomics technologies. This strategic approach is expected to support the long-term financial health and innovation within the division[3].

Regional Performance

Geographic Sales Distribution

• Ultravist exports are distributed across various regions, with significant sales in Europe, Asia, and Latin America. The product's performance in these regions is influenced by local healthcare needs, regulatory environments, and market competition[1].

Regional Market Growth

• In Europe, the Pharmaceuticals division of Bayer has seen higher sales driven by products like Iberogast and Rennie. Similarly, in Asia, particularly in China, there has been strong demand for regional brands, contributing to the overall growth of the division[3].

Challenges and Opportunities

Currency and Market Fluctuations

• The sales of Ultravist, like other pharmaceutical products, are affected by currency fluctuations and market conditions. For example, in the first quarter of 2024, Bayer faced negative currency effects that impacted its overall financial performance[3].

Regulatory and Reimbursement Milestones

• Regulatory approvals and reimbursement milestones are crucial for the continued success of Ultravist. Bayer's ability to navigate these regulatory environments effectively will be key to maintaining and expanding market share[3].

Key Takeaways

• Export Growth: Ultravist exports have shown a 4% growth rate over the past year, despite recent monthly declines.
• Revenue Contribution: The product is a significant contributor to Bayer's Pharmaceuticals division, which saw a 3.9% sales increase in the first quarter of 2024.
• Pricing Dynamics: Pricing varies based on volume and concentration, reflecting market demand and competition.
• Regional Performance: Strong sales in Europe, Asia, and Latin America, driven by local healthcare needs and market conditions.
• Financial Outlook: Stable or increased sales expected in 2024, supported by cost management and R&D investments.

FAQs

What is Ultravist 150 used for?

Ultravist 150 is a non-ionic, iodinated contrast medium used in various medical imaging procedures such as CT scans, angiography, and other radiographic examinations.

Who are the main exporters of Ultravist?

Germany, India, and Turkey are the top exporters of Ultravist, with Germany leading the global exports[1].

How has the sales performance of Ultravist been in recent quarters?

In the first quarter of 2024, the Radiology segment, which includes Ultravist, saw a growth of around 10% (currency- and portfolio-adjusted)[3].

What are the key challenges facing Ultravist in the market?

Ultravist faces challenges such as currency fluctuations, competitive pressure from generic products, and regulatory environments that can impact sales and market share[3].

What is Bayer's financial outlook for the Pharmaceuticals division in 2024?

Bayer expects stable or slightly increased sales in the Pharmaceuticals division in 2024, supported by continued growth in new products and cost management efforts[3].

Sources

1. Volza.com: Ultravist Exports from World - Volza.com
2. Ultragenyx: Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
3. Bayer: First-quarter performance as expected - Bayer
4. Ultragenyx: Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update (PDF)
5. Bayer: Modest performance in challenging agricultural market environment – Group outlook confirmed